Editing Positron emission tomography (section)

=== Limitations ===
The minimization of radiation dose to the subject is an attractive feature of the use of short-lived radionuclides. Besides its established role as a diagnostic technique, PET has an expanding role as a method to assess the response to therapy, in particular, cancer therapy,<ref>{{cite journal | vauthors = Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P | display-authors = 6 | title = Measurement of clinical and subclinical tumor response using [<sup>18</sup>F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group | journal = European Journal of Cancer | volume = 35 | issue = 13 | pages = 1773–1782 | date = December 1999 | pmid = 10673991 | doi = 10.1016/S0959-8049(99)00229-4 }}</ref> where the risk to the patient from lack of knowledge about disease progress is much greater than the risk from the test radiation. Since the tracers are radioactive, the elderly{{Dubious|date=January 2020}} and pregnant are unable to use it due to risks posed by radiation.

Limitations to the widespread use of PET arise from the high costs of cyclotrons needed to produce the short-lived radionuclides for PET scanning and the need for specially adapted on-site chemical synthesis apparatus to produce the radiopharmaceuticals after radioisotope preparation. Organic radiotracer molecules that will contain a positron-emitting radioisotope cannot be synthesized first and then the radioisotope prepared within them, because bombardment with a cyclotron to prepare the radioisotope destroys any organic carrier for it. Instead, the isotope must be prepared first, then the chemistry to prepare any organic radiotracer (such as FDG) accomplished very quickly, in the short time before the isotope decays. Few hospitals and universities are capable of maintaining such systems, and most clinical PET is supported by third-party suppliers of radiotracers that can supply many sites simultaneously. This limitation restricts clinical PET primarily to the use of tracers labelled with fluorine-18, which has a half-life of 110 minutes and can be transported a reasonable distance before use, or to rubidium-82 (used as [[rubidium-82 chloride]]) with a half-life of 1.27 minutes, which is created in a portable generator and is used for [[myocardium|myocardial]] [[perfusion]] studies. In recent years a few on-site cyclotrons with integrated shielding and "hot labs" (automated chemistry labs that are able to work with radioisotopes) have begun to accompany PET units to remote hospitals. The presence of the small on-site cyclotron promises to expand in the future as the cyclotrons shrink in response to the high cost of isotope transportation to remote PET machines.<ref>{{cite web |url=http://www.medicalimagingmag.com/issues/articles/2003-07_05.asp |title=Technology | vauthors = Fratt L |date=July 2003 |website=Medical Imaging |url-status=dead |archive-url=https://web.archive.org/web/20081120152623/http://www.medicalimagingmag.com/issues/articles/2003-07_05.asp |archive-date=November 20, 2008 }}</ref> In recent years{{when|date=May 2025}} the shortage of PET scans has been alleviated in the US, as rollout of [[Nuclear pharmacy|radiopharmacies]] to supply radioisotopes has grown 30 percent per year.<ref>{{cite web |title=PET History and Overview |date=January 16, 2013 |url=http://www.crump.ucla.edu/start/course/Lecture%206%20-%20PET%20History%20and%20Overview.pdf | vauthors = Phelps M |publisher=Crump Institute for Molecular Imaging |url-status=dead |archive-url=https://web.archive.org/web/20150518082954/http://www.crump.ucla.edu/start/course/Lecture%206%20-%20PET%20History%20and%20Overview.pdf |archive-date=May 18, 2015 }}</ref>

Because the half-life of fluorine-18 is about two hours, the prepared dose of a radiopharmaceutical bearing this radionuclide will undergo multiple half-lives of decay during the working day. This necessitates frequent recalibration of the remaining dose (determination of activity per unit volume) and careful planning with respect to patient scheduling.